Research programme: complement inhibitors - Amyndas Pharmaceuticals

Drug Profile

Research programme: complement inhibitors - Amyndas Pharmaceuticals

Alternative Names: AMANDEN; AMY 201; AMY-112; Compsorbin; Compstatin analogues - Amyndas; Cp 40

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Amyndas Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 26 Oct 2017 Preclinical trials in Age-related macular degeneration in USA before October 2017 (Amyndas Pharmaceuticals website, October 2017)
  • 27 Feb 2017 Amyndas has issued and pending patents with USPTO and PCT for complement inhibitors (Amyndas website, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top